NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?

Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.

Zacks Investment Research • Jul 9, 2026

A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics

Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.

The Motley Fool • Jul 8, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on July 1, 2026, it awarded inducement grants to thirteen new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

GlobeNewsWire • Jul 6, 2026

Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%

One of Intellia Therapeutics' leading candidates recently aced a phase 3 study. The company has another late-stage asset with an even better commercial opportunity.

The Motley Fool • Jul 1, 2026

Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze

Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if sentiment flips.

Benzinga • Jun 29, 2026

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

Intellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipeline of CRISPR-based gene editing therapies. Omeros recently entered the commercial stage with the FDA approval of Yartemlea and a significant development deal with Novo Nordisk.

The Motley Fool • Jun 20, 2026

This Stock Is Up 58% This Year. Is It too Late to Buy?

One of Intellia Therapeutics' leading candidates recently aced a phase 3 study. This medicine's commercial opportunity is somewhat limited.

The Motley Fool • Jun 17, 2026

Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?

Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Jun 16, 2026

NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up

Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by 89% and moderate-to-severe episodes by 91%.

Zacks Investment Research • Jun 16, 2026

Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder

Intellia Therapeutics, Inc. (NASDAQ:NTLA) stock is trading higher on Monday on additional positive findings from its global Phase 3 HAELO trial evaluating lonvo-z, its investigational CRISPR-based treatment for hereditary angioedema (HAE).

Benzinga • Jun 15, 2026